HERBIOTA Trademark
Trademark Overview
On Friday, August 9, 2024, a trademark application was filed for HERBIOTA with the United States Patent and Trademark Office. The USPTO has given the HERBIOTA trademark a serial number of 98691053. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, August 9, 2024. This trademark is owned by Heranova Biosciences Inc. The HERBIOTA trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical diagnostic assay test and analysis for the presence of biomarkers in uterine tissue for determining a patient's personalized treatment plan; medical diagnostic assay test and analysis for the presence normal lactobacillus and targeted pathogenic bacteria, namely Escherichia, Klebsiella, Enterococcus, Streptococcus, Mycoplasma, Chlamydia, Ureaplasma, Neisseria, Staphylococcus, and Gardnerella.
Providing medical information in the field of gynecology; medical information services in the gynecological field, namely endometritis; medical diagnostic services for gynecological conditions; medical testing services for diagnostic purposes in the field of gynecology; medical testing services, namely testing services for detecting endometritis, Pelvic Inflammatory Disease and antibiotic resistance either post-partum or in cases of unexplained infertility.
General Information
| Serial Number | 98691053 |
| Word Mark | HERBIOTA |
| Filing Date | Friday, August 9, 2024 |
| Status | 630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER |
| Status Date | Friday, August 9, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Medical diagnostic assay test and analysis for the presence of biomarkers in uterine tissue for determining a patient's personalized treatment plan; medical diagnostic assay test and analysis for the presence normal lactobacillus and targeted pathogenic bacteria, namely Escherichia, Klebsiella, Enterococcus, Streptococcus, Mycoplasma, Chlamydia, Ureaplasma, Neisseria, Staphylococcus, and Gardnerella. |
| Goods and Services | Providing medical information in the field of gynecology; medical information services in the gynecological field, namely endometritis; medical diagnostic services for gynecological conditions; medical testing services for diagnostic purposes in the field of gynecology; medical testing services, namely testing services for detecting endometritis, Pelvic Inflammatory Disease and antibiotic resistance either post-partum or in cases of unexplained infertility. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 9, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 9, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Heranova Biosciences Inc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Burlington, MA 01803 |
Trademark Events
| Event Date | Event Description |
| Friday, August 9, 2024 | NEW APPLICATION ENTERED |
